Ingredion Divests Rafhan Maize Majority Stake, Focuses on Specialty Ingredients

London, United Kingdom — 02 July 2026

Ingredion has divested a 51% interest in Rafhan Maize, its Pakistan-based food and industrial ingredient manufacturing subsidiary, generating approximately US$165 million. The deal, which leaves Ingredion with a 20% minority stake, is a deliberate move to reduce earnings volatility and reallocate capital towards higher-growth specialty ingredient sectors. This divestiture aligns with Ingredion’s broader strategic reorientation, underscored by its proposed £2.7 billion acquisition of Tate & Lyle, a major consolidation within the global food ingredients market.

The sale to a consortium led by Nishat Hotels and Properties Ltd. follows Ingredion's full-year 2025 unaudited net sales from its Pakistan operations, which totalled approximately US$250 million. CEO Jim Zallie stated that maintaining a minority interest provides continuous access to the Middle East and South Asia markets, which are identified as long-term growth platforms, while transitioning to a capital-light operational structure in the region. This strategy allows Ingredion to maintain commercial ties without the full operational burden, freeing investment capital for core specialty ingredient expansion.

The impending acquisition of Tate & Lyle, unanimously backed by its board in June, is expected to complete by the second half of 2027, subject to customary approvals. This merger is set to create a formidable specialty ingredients enterprise, with combined revenues projected at US$9.9 billion and an adjusted EBITDA of US$1.8 billion. The enlarged portfolio will bolster Ingredion’s capabilities in areas like texture, sugar reduction, mouthfeel, and fortification, which are key drivers for product reformulation within the food and beverage industry.

Tate & Lyle’s own strategic initiatives, including its 2024 acquisition of CP Kelco, reflect an industry-wide trend towards enhancing specialty capabilities. These ongoing consolidations and portfolio adjustments indicate a clear industry shift towards valued-added ingredient solutions driven by health, affordability, and clean label consumer demands, rather than commodity-linked volume. Brand owners and manufacturers should anticipate intensified competition and potentially reconfigured supply chains as these consolidated entities leverage their expanded technological and market reach.

What this means for United Kingdom

UK supplement and food manufacturers will face a consolidated and more vertically integrated supply chain for core specialty ingredients. Ingredion's acquisition of Tate & Lyle means reduced supplier choice in texture, sugar reduction, and fortification, potentially impacting procurement leverage. Formulation teams must evaluate alternative suppliers or prepare for revised MOQs and lead times from the combined entity by H2 2027. Ingredient costs for key functional components could stabilise or increase, necessitating margin re-evaluation for product lines dependent on these suppliers. This consolidation also presents an opportunity for UK innovators to partner with a stronger, more capable ingredients provider for novel product development aiming for health and clean-label appeals.

What to watch next

• Monitor regulatory approval timelines for the Ingredion-Tate & Lyle merger, with a completion target in the second half of 2027, as this will dictate the formal integration and market impact.
• Observe the strategic investment priorities and product development pipelines of the combined Ingredion-Tate & Lyle entity in early 2028 to identify new ingredient offerings and competitive shifts in the European market.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.